Personalized approaches to clopidogrel therapy: are we there yet?
Anderson
Christopher D
CD
Division of Neurocritical Care and Emergency Neurology, Stroke Service, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.
Biffi
Alessandro
A
Greenberg
Steven M
SM
Rosand
Jonathan
J
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D001777:Blood Coagulation / Q000187:drug effects / Q000235:genetics; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D057285:Precision Medicine / Q000379:methods*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine